Literature DB >> 28629543

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

Alexa B Schrock1, Andrea Lai2, Siraj M Ali3, Vincent A Miller3, Luis E Raez4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28629543     DOI： 10.1016/j.jtho.2017.02.017

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.

Authors:  Caiwen Huang; Qihua Zou; Hui Liu; Bo Qiu; Qiwen Li; Yongbin Lin; Ying Liang
Journal:  Curr Treat Options Oncol       Date:  2020-04-18

Review 2.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

Review 3.  Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.

Authors:  Xing Huang; Enliang Li; Hang Shen; Xun Wang; Tianyu Tang; Xiaozhen Zhang; Jian Xu; Zengwei Tang; Chengxiang Guo; Xueli Bai; Tingbo Liang
Journal:  Front Cell Dev Biol       Date:  2020-05-06

4.  Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.

Authors:  Gavin W Collie; Iacovos N Michaelides; Kevin Embrey; Christopher J Stubbs; Ulf Börjesson; Ian L Dale; Arjan Snijder; Louise Barlind; Kun Song; Puneet Khurana; Christopher Phillips; R Ian Storer
Journal:  ACS Med Chem Lett       Date:  2020-12-08       Impact factor: 4.345

Review 5.  A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.

Authors:  Mariacarmela Santarpia; Marco Massafra; Vittorio Gebbia; Antonio D'Aquino; Claudia Garipoli; Giuseppe Altavilla; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2021-03

6.  Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.

Authors:  Takashi Seto; Kadoaki Ohashi; Shunichi Sugawara; Makoto Nishio; Masayuki Takeda; Keisuke Aoe; Sanae Moizumi; Satoshi Nomura; Takeshi Tajima; Toyoaki Hida
Journal:  Cancer Sci       Date:  2021-02-24       Impact factor: 6.716

Review 7.  Targeting HGF/c-MET Axis in Pancreatic Cancer.

Authors:  Srinivasa P Pothula; Zhihong Xu; David Goldstein; Romano C Pirola; Jeremy S Wilson; Minoti V Apte
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

Review 8.  Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Authors:  Takamasa Koga; Kenichi Suda; Tetsuya Mitsudomi
Journal:  Cancer Sci       Date:  2022-01-23       Impact factor: 6.716

9.  Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

Authors:  Trever G Bivona; Collin M Blakely; Julia K Rotow; Philippe Gui; Wei Wu; Victoria M Raymond; Richard B Lanman; Frederic J Kaye; Nir Peled; Ferran Fece de la Cruz; Brandon Nadres; Ryan B Corcoran; Iwei Yeh; Boris C Bastian; Petr Starostik; Kimberly Newsom; Victor R Olivas; Alexander M Wolff; James S Fraser; Eric A Collisson; Caroline E McCoach; D Ross Camidge; Jose Pacheco; Lyudmila Bazhenova; Tianhong Li
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.